Literature DB >> 18451874

Initial results of QuantiFERON-TB Gold testing in patients with uveitis.

S Itty1, S J Bakri, J S Pulido, D C Herman, L J Faia, G T Tufty, S R Bennett, N S Falk.   

Abstract

PURPOSE: To describe the use of the second-generation QuantiFERON-TB Gold (QFT-G) test in a series of patients in an ophthalmic practice.
METHODS: The charts of all patients who had QFT-G tests ordered by Mayo Clinic ophthalmologists in the past 3 years were reviewed.
RESULTS: A total of 27 QFT-G tests were ordered. Thirteen (48%) tests were negative, six (22%) were indeterminate, two (7%) tests were re-ordered after a lab accident or an improper cancellation, four (15%) were positive and represented infection, and two (7%) were positive but negative when re-tested. Of the four truly positive cases, three were treated for tuberculosis (TB): one had tuberculous iritis, one had retinal vasculitis and haemorrhage, and one had asymptomatic TB but was on immunosuppressive therapy. The fourth patient had previously been treated for latent infection.
CONCLUSIONS: In a series of selected patients with uveitis, the QFT-G test was able to detect TB infection in 15% of the patients, though it does not differentiate between active and latent TB infection. QFT-G should be considered in place of purified protein derivative testing in those with uveitis that have had prior BCG vaccination and in immunocompromised patients. Patients with a positive QFT-G, but who have little risk for TB infection and a negative systemic work-up, should be re-tested.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18451874     DOI: 10.1038/eye.2008.115

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  13 in total

Review 1.  Current approach in the diagnosis and management of panuveitis.

Authors:  Reema Bansal; Vishali Gupta; Amod Gupta
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

2.  Clinical presentation, treatment, and outcomes in presumed intraocular tuberculosis: experience from Newcastle upon Tyne, UK.

Authors:  K Manousaridis; E Ong; C Stenton; R Gupta; A C Browning; R Pandit
Journal:  Eye (Lond)       Date:  2013-02-22       Impact factor: 3.775

3.  Caveats about QuantiFERON-TB gold in-tube testing for uveitis.

Authors:  Kathryn L Pepple; Russell Van Gelder; Farzin Forooghian
Journal:  Am J Ophthalmol       Date:  2014-04       Impact factor: 5.258

4.  Ocular Tuberculosis--A Clinical Conundrum.

Authors:  Cecilia Lee; Rupesh Agrawal; Carlos Pavesio
Journal:  Ocul Immunol Inflamm       Date:  2015-06-25       Impact factor: 3.070

5.  Utility of QuantiFERON®-TB Gold test in diagnosis and management of suspected tubercular uveitis in India.

Authors:  S Sudharshan; Sudha K Ganesh; G Balu; B Mahalakshmi; Lily K Therese; H N Madhavan; Jyotirmay Biswas
Journal:  Int Ophthalmol       Date:  2012-04-15       Impact factor: 2.031

6.  Appraisal, work-up and diagnosis of anterior uveitis: a practical approach.

Authors:  Carl P Herbort
Journal:  Middle East Afr J Ophthalmol       Date:  2009-10

7.  Structural changes of the choroid in sarcoid- and tuberculosis-related granulomatous uveitis.

Authors:  H Mehta; D A Sim; P A Keane; J Zarranz-Ventura; K Gallagher; C A Egan; M Westcott; R W J Lee; A Tufail; C E Pavesio
Journal:  Eye (Lond)       Date:  2015-05-29       Impact factor: 3.775

8.  From the editor's desk - vasculitis my brief synopsis.

Authors:  S Natarajan
Journal:  Indian J Ophthalmol       Date:  2011 Jul-Aug       Impact factor: 1.848

9.  The Association between QuantiFERON-TB Gold Test and Clinical Manifestations of Uveitis in the United States.

Authors:  Mehmet Yakin; Natasha Kesav; Shuk Kei Cheng; Sonny Caplash; Sapna Gangaputra; H Nida Sen
Journal:  Am J Ophthalmol       Date:  2021-05-02       Impact factor: 5.488

10.  Utility of QuantiFERON TB gold test in a south Indian patient population of ocular inflammation.

Authors:  Kalpana Babu; Vidya Satish; S Satish; D K Subbakrishna; Mariamma Philips Abraham; Krishna R Murthy
Journal:  Indian J Ophthalmol       Date:  2009 Nov-Dec       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.